DrugDashboards

Trospium Chloride ER

Trospium Chloride · TROSPIUM CHLORIDE 60 mg/1 · Capsule, Extended Release · Oral · Padagis US LLC

NDC 00574-0118-30 · 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 12% over the past year, to $1.68 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$1.68per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$3.23per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$3.71per unitnegotiated price across 2,815 plans — before rebates · Jan 1, 2024
  • Federal contracts pay (FSS)$1.21per unitPadagis Sourcing Solutions LLC · Sep 21, 202272% of what pharmacies pay — a deeper discount than 71% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$1.68per CAPweighted avg manufacturer price $0.7347 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.71per unit
middle half $2.19$4.85 · 2,815 plans · Jan 1, 2024
Est. net of rebates
≈ $3.71
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Nov 2013Sep 2026$1.68
155 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$50.28
#90 count
$150.83

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$196,943
2,388 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for trospium chloride (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA201291
TE code
AB
Approval date
May 24, 2013
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingNov 1, 2023
    Padagis US LLCFailed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules

Manufacturers of Trospium Chloride (Capsule, Extended Release)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackTROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 3, 2026
Actavis Pharma, Inc.TROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Bluepoint LaboratoriesTROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Golden State Medical Supply, Inc.TROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.TROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Padagis US LLCTROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Proficient Rx LPTROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Slate Run Pharmaceuticals, LLCTROSPIUM CHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Trospium Chloride ER — NDC 00574-0118-30," retrieved September 3, 2026, https://drugdashboards.com/drug/00574011830.

Free to cite with attribution — see how the data is put together.